Astrin K H, Desnick R J
Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029.
Hum Mutat. 1994;4(4):243-52. doi: 10.1002/humu.1380040403.
Acute intermittent porphyria (AIP) is an autosomal dominant inborn error of metabolism that results from the half-normal activity of the third enzyme in the heme biosynthetic pathway, hydroxymethylbilane synthase (HMB-synthase). AIP is an ecogenetic condition, with life-threatening acute attacks precipitated by various factors including drugs, alcohol, fasting, and certain hormones. Biochemical diagnosis is problematic and the identification of mutations in the HMB-synthase gene provides accurate detection of presymptomatic heterozygotes, permitting avoidance of the acute precipitating factors. Two HMB-synthase isozymes are encoded by the HMB-synthase gene: one unique to erythroid cells and the other a housekeeping isozyme present in all cells. These two isozymes arise from a single gene by alternative splicing. The recent isolation of the cDNAs and entire genomic sequence encoding the HMB-synthase isozymes has facilitated the detection of diagnostically useful intragenic polymorphisms and disease-causing mutations. Of the 36 mutations identified to date, most caused the classic form of AIP. These mutations included small deletions and insertions, point mutations and RNA splice junction alterations and resulted in the half-normal activity of both the erythroid-specific and housekeeping isozymes. Most AIP mutations were private; however, certain mutations were frequently found in Dutch (R116W) and Swedish (W198X) AIP families. A variant form of AIP, in which patients have normal erythroid activity, but half-normal activity of the housekeeping isozyme, resulted from two mutations at the exon 1/intron 1 boundary, each altering splicing of the hepatic-specific transcript. In addition, 10 polymorphisms in the HMB-synthase gene have been identified that are useful for the diagnosis of presymptomatic AIP heterozygotes in families whose specific mutations have not been determined.
急性间歇性卟啉病(AIP)是一种常染色体显性遗传的先天性代谢紊乱疾病,由血红素生物合成途径中第三种酶——羟甲基胆色素原合酶(HMB合酶)活性减半所致。AIP是一种遗传环境相关疾病,药物、酒精、禁食和某些激素等多种因素可诱发危及生命的急性发作。生化诊断存在问题,而HMB合酶基因突变的鉴定可准确检测出症状前杂合子,从而避免急性诱发因素。HMB合酶基因编码两种HMB合酶同工酶:一种是红细胞特异性的,另一种是所有细胞中都存在的管家同工酶。这两种同工酶由一个基因通过可变剪接产生。最近分离出编码HMB合酶同工酶的cDNA和完整基因组序列,有助于检测具有诊断价值的基因内多态性和致病突变。迄今为止鉴定出的36种突变中,大多数导致经典形式的AIP。这些突变包括小缺失、插入、点突变和RNA剪接连接改变,导致红细胞特异性和管家同工酶活性均减半。大多数AIP突变是个体特有的;然而,某些突变在荷兰(R116W)和瑞典(W198X)的AIP家族中经常出现。AIP的一种变异形式是,患者的红细胞活性正常,但管家同工酶活性减半,这是由外显子1/内含子1边界处的两个突变导致的,每个突变都改变了肝脏特异性转录本的剪接。此外,已鉴定出HMB合酶基因中的10种多态性,这些多态性可用于诊断特定突变尚未确定的家族中症状前AIP杂合子。